Since its inception in 2016, the fund has achieved the following 
  • 53% of eligible Quad faculty applied
  • Reviewed 216 grant proposals
  • Q-FASTR awardees had 6 new start-up companies and close to $349 million in follow-on funding, which corresponds to 22 times our investment

Q-FASTR is dedicated to transforming cutting-edge basic research at HMS into tomorrow’s therapeutics, diagnostics, and related technologies. By championing early ideas and enveloping them with financial and scientific support, we cultivate breakthroughs that have the potential to reshape medicine.

Ifat Rubin-Bejerano
Senior Director, Translational Research Programs, Harvard Medical School